Description: Ultragenyx Pharmaceutical Inc., a development-stage biotechnology company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare diseases in the United States. It develops various biologics product candidates, including KRN23, a human monoclonal antibody to bind and reduce the biological activity of fibroblast growth factor to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia; recombinant human beta-glucuronidase, an intravenous enzyme replacement therapy for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A, an enzyme replacement therapy for galactosialidosis. The company is also developing a range of small-molecule product candidates comprising triheptanoin, a substrate replacement therapy for patients with fatty acid oxidation disorders, as well as for patients with glucose transporter type-1 deficiency syndrome; and oral formulation of sialic acid to treat hereditary inclusion body myopathy. It has license agreements with AAI Pharma Services Corp. and HIBM Research Group; and a collaboration and license agreement with Nobelpharma Co., Ltd. The company was founded in 2010 and is headquartered in Novato, California.
Home Page: www.ultragenyx.com
RARE Technical Analysis
60 Leveroni Court
Novato,
CA
94949
United States
Phone:
415 483 8800
Officers
| Name | Title |
|---|---|
| Dr. Emil D. Kakkis M.D., Ph.D. | Founder, Pres, CEO & Director |
| Mr. John Richard Pinion II | Chief Quality Operations Officer & Exec. VP of Translational Sciences |
| Dr. Camille L. Bedrosian M.D. | Chief Medical Officer & Exec. VP |
| Mr. Erik Harris | Exec. VP & Chief Commercial Officer |
| Mr. Theodore A. Huizenga | Sr. VP, Corp. Controller & Principal Accounting Officer |
| Mr. Dennis Karl Huang | Chief Technical Operations Officer & Exec. VP |
| Ms. Danielle Keatley | Sr. Director of Investor Relations & Corp. Communications |
| Ms. Karah Herdman Parschauer J.D. | Chief Legal Officer & Exec. VP |
| Mr. Ernie W. Meyer | Chief HR Officer & Exec. VP |
| Mr. Thomas R. Kassberg | Chief Bus. Officer & Exec. VP |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 6.7978 |
| Price-to-Sales TTM: | 9.304 |
| IPO Date: | 2014-01-31 |
| Fiscal Year End: | December |
| Full Time Employees: | 1119 |